Professional Documents
Culture Documents
SCHEDULE OF EVENTS
May 10, 2016 | Linder Reading Room, Michael F. Sorrell Center, UNMC | Omaha, Nebraska
9 a.m.
Opening Remarks
Welcome to
UNeMeds
2016 Industry
Partnering
Summit
IKK-beta inhibitors:
Amar Natarajan, Ph.D.
1:55 p.m.
Targeted radiopharmaceuticals:
Calidum, Inc.
UNeMed.com | 402.559.2468
UNMC Technology
Prevents
future
disease,
treats
existing
disease
UNeMed.com | 402.559.2468
UNMC Technology
27 times more
potent than
vancomycin
against staph
UNMC Technology
Improve
brain & heart
function in
diabetic
patients
UNeMed.com | 402.559.2468
UNMC Technology
UNeMed.com | 402.559.2468
UNMC Technology
Significant
inhibition
of tumor
growth in
animal
studies
UNeMed.com | 402.559.2468
UNMC Technology
IKK-beta inhibitors
Researchers at UNMC have identified a set of compounds that act as inhibitors of the NF-B pathway and specifically inhibit IKK. Initial work has
focused on the lead compound called 13-197.
13-197 has been evaluated using a wide variety of in vitro assays and
demonstrated antiproliferative activity against a
panel of cancer cell lines. It also inhibited NF-B
mediated gene transcription, enhanced caspase
3/7 activity, induced apoptosis, and sensitized
pancreatic cancer cells to gemcitabine.
13-197 has been tested in two different
in vivo cancer models. In an orthotopic mouse
model of pancreatic cancer, 13-197 significantly decreased tumor size and tumor metastasis. 13-197 also decreased inflammation and
microvessel density within the pancreatic tumors while increasing tumor necrosis.
13-197has also been tested in a mouse model of mantle cell lymphoma where it reduced tumor burden in the kidney, liver and lungs, and
significantly increased the overall survival of the
mice.
Researchers are now working on developing
additional analogs of 13-197, and hope to advance into the clinic soon.
Potent
inhibitor
of cancer cell
proliferation
Back
UNeMed.com | 402.559.2468
UNMC Technology
Longer-lasting
and more
effective than
traditional
daily
treatments
UNeMed.com | 402.559.2468
Back
UNMC Startup
Prommune Inc.
is a research and
development company
that has created a
unique and patented
means to safely and
effectively awaken the
bodys own natural
immune defenses
without inflammatory
side-effects
UNeMed.com | 402.559.2468
10
UNMC Startup
Calidum Inc.
is developing
products based on
a novel concept of
receptor-targeted
& DNA co-targeted
delivery of radiation
directly to the DNA
of a cancer cell
UNeMed.com | 402.559.2468
UNMC Startup
11
Nanoformulations for
treating acute spinal cord injury
ProTransit
Nanotherapy LLC is
developing therapies
based on potent
biomacromolecular
therapuetics
using patented
nanoparticle
technology
UNeMed.com | 402.559.2468
12
Poster Titles
CD74-based gene therapy for
Alzheimers disease (Tomomi Kiyota, Ph.D.)
Development of subtype selective
NMDA modulators (Dan Monaghan, Ph.D.)
New approaches for the diagnosis & treatment
of pancreatic cancer (Surinder Batra, Ph.D.)
Role of miR-133a in pathophysiology of
diabetic hearts (Paras Kumar Mishra, Ph.D.)
Screen to identify genes that are essential
and selective for tumor cells (Rob Lewis, Ph.D.)
Antimicrobial peptides and UNMCs
antimicrobial peptide database (Gus Wang, Ph.D.)
Pancreatic Differentiation Factor 2 a target for
the treatment of cancer (Surinder Batra, Ph.D.)
Department Overviews
Dept. of Pharmacology and
Experimental Neuroscience
Chair: Howard Gendelman, M.D.
UNeMed.com | 402.559.2468
25TH ANNIVERSARY